Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women

Labrie, Fernand; Cusan, Lionel; Gómez, José L.; Côté, Isabelle; Bérubé, René; Bélanger, Patrick; Martel, Céline; Labrie, Claude

doi:10.1016/j.jsbmb.2008.06.003

Cited by 93 publications

(89 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For selectivity and specificity tests, pooled stripped blank serum, 20 lots of unstripped serum, cross interference of internal standards to analytes or analytes to internal standards, metabolites converion of Testo-glucuronide, E 1 sulphate and DHEA sulphate were examined,where the sample were prepared in a same manner as GC-MS/MS sample preparation procdure was the same as described in literature [24,25]. The acceptance criteria of incurred sample reanalysis (ISR) [26] was applied for these unknown sample comparisons, which is that 67% of the sample results should be within 20% for small molecules where the percentage difference of the results was determined with the following equation …”

Section: Selectivity and Specificitymentioning

confidence: 99%

A sensitive, simple and robust LC–MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum

Ke¹,

Bertin²,

Gonthier³

et al. 2014

The Journal of Steroid Biochemistry and Molecular Biology

Self Cite

122

View full text Add to dashboard Cite

Section: Selectivity and Specificitymentioning

confidence: 99%

A sensitive, simple and robust LC–MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum

Ke¹,

Bertin²,

Gonthier³

et al. 2014

The Journal of Steroid Biochemistry and Molecular Biology

Self Cite

122

View full text Add to dashboard Cite

“…Changes in serum estradiol (E 2 ) during the 24-hour period after the seventh daily intravaginal administration of 0.5% dehydroepiandrosterone (DHEA; n = 10), 1.0% DHEA (n = 10), 25 Kg E 2 (n = 10; Vagifem), and 0.625 Kg conjugated estrogens (Premarin cream; n = 10). 2,10,11 true changes in androgen formation, whereas the overestimation of estrogen production is even higher 16 (Fig. 3).…”

Section: As Illustrated In Figures 1 and 2 And Shown Inmentioning

confidence: 94%

“…Serum steroid levels of DHEA, DHEA-S, androst-5-ene-3A,17A-diol (5-diol), DHT, testosterone, 4-dione, E 1 , E 2 , E 1 -S, androsterone glucuronide (ADT-G), androstane-3>,17A-diol-3 glucuronide (3>-diol-3 G), and 3>-diol-17 G were measured at the Laboratory of Molecular Endocrinology, Laval University Hospital Research Center, by mass spectrometry according to Good Laboratory PracticeY validated methodology as described. 3,10,14 Intra-assay and interassay coefficients of variation were reported.…”

Section: Laboratory Testsmentioning

confidence: 99%

Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration

et al. 2009

Self Cite

View full text Add to dashboard Cite

The present data show that local daily intravaginal DHEA administration at DHEA doses of 3.25-13 mg was able to rapidly and efficiently achieve correction of all the signs and symptoms of vaginal atrophy and improve sexual function and caused no or minimal changes in serum sex steroid levels, which all remain within the normal postmenopausal range, thus avoiding the risks of all estrogen formulations.

show abstract

“…the impact of a daily intravaginal application of 1 ovule DHEA (at three different concentrations), a precursor to androgens and estrogens, on vaginal maturation and vaginal pH 65. In this study, 7 days of treatment significantly increased vaginal maturation and significantly decreased vaginal pH.…”

mentioning

confidence: 62%

Recognizing and Treating Urogenital Atrophy in Postmenopausal Women

Goldstein

2010

Journal of Women's Health

View full text Add to dashboard Cite

Urogenital atrophy resulting from postmenopausal estrogen deficiency has numerous clinical effects, including vaginal dryness, sexual dysfunction, urinary incontinence, and recurrent urinary tract infections (UTIs), all of which can cause significant distress and reduction in quality of life. Although nearly one third to one half of postmenopausal women experience these symptoms, they are often overlooked because patients may be reluctant to discuss them and clinicians fail to screen for them. As these symptoms are unlikely to resolve without treatment, the prompt diagnosis and treatment of urogenital atrophy is essential. Estrogen therapy, administered either locally or systemically, provides significant relief from symptoms related to urogenital atrophy. However, systemic estrogen therapy is contraindicated in some women and may not be accepted in women without other menopausal symptoms. Local low-dose vaginal estrogen therapy, in the form of vaginal estrogen tablets, creams, or rings, has been shown to reduce dyspareunia and vaginal dryness, restore vaginal pH, and restore normal vaginal cytology. All forms of vaginal estrogen therapy are effective and well tolerated, although vaginal tablets and rings may have fewer adverse effects and have higher rates of adherence than creams.

show abstract

Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women

Cited by 93 publications

References 44 publications

A sensitive, simple and robust LC–MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum

A sensitive, simple and robust LC–MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum

Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration

Recognizing and Treating Urogenital Atrophy in Postmenopausal Women

Contact Info

Product

Resources

About